Albert Bourla, CEO of Pfizer attends a dialogue on the World Financial Discussion board (WEF) in Davos, Switzerland Might 25, 2022. REUTERS/Arnd Wiegmann
Register now for FREE limitless entry to Reuters.com
Sept 24 (Reuters) – Pfizer Inc (PFE.N) Chief Government Officer Albert Bourla mentioned on Saturday he had examined constructive for COVID-19.
“I’m feeling nicely and symptom free,” Bourla mentioned in a press release.
Bourla, 60, again in August had contacted COVID and had began a course of the corporate’s oral COVID-19 antiviral therapy, Paxlovid. learn extra
Register now for FREE limitless entry to Reuters.com
Paxlovid is an antiviral treatment that’s used to deal with high-risk folks, akin to older sufferers.
Bourla has obtained 4 doses of the COVID vaccine developed by Pfizer and its German associate BioNTech (22UAy.DE).
The chief government mentioned he has not but taken the brand new bivalent booster.
Developed by Moderna and the crew of Pfizer and BioNTech, the brand new so-called bivalent pictures goal to sort out the BA.5 and BA.4 Omicron subvariants, which make up 84.8% and 1.8%, respectively, of all circulating variants in the USA, based mostly on newest knowledge.
“I’ve not had the brand new bivalent booster but, as I used to be following CDC pointers to attend three months since my earlier COVID case which was again in mid-August,” Bourla added.
In August, the FDA approved Pfizer and Moderna’s up to date booster pictures that concentrate on the dominant BA.4 and BA.5 Omicron subvariants.
A federal well being company mentioned this week that over 25 million doses of the so-called bivalent pictures had been despatched out. That consisted of principally the Pfizer/BioNTech vaccine, as manufacturing of the Moderna vaccine ramps up. learn extra
Register now for FREE limitless entry to Reuters.com
Reporting by Mrinmay Dey in Bengaluru; Modifying by Daniel Wallis
: .
